Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

BACKGROUND: Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic andcentral nervous system adverse events. We report a case of anti-N-methyl-...

Descripción completa

Detalles Bibliográficos
Autores principales: Karunaratne, Kushan, Ahrabian, Dariush, Monaghan, Bernadette, Campion, Tom, Yousry, Tarek, Lunn, Michael P, Zandi, Michael S, Howard, Robin S, Kullmann, Dimitri M, Spillane, Jennifer, Walker, Matthew, Chataway, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137234/
https://www.ncbi.nlm.nih.gov/pubmed/34079936
http://dx.doi.org/10.1136/bmjno-2020-000096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137234/
https://www.ncbi.nlm.nih.gov/pubmed/34079936
http://dx.doi.org/10.1136/bmjno-2020-000096

Ejemplares similares